A single center randomized study comparing the efficacy of sulbactam/cefoperazone + amikacin vs ceftazidim + amikacin in febrile neutropenic patients FEBRIL NOTROPENIK HASTALARDA TEK MERKEZLI RANDOMIZE BIR CALISMADA SULBAKTAM/SEFOPERAZON + AMIKASIN ILE SEFTAZIDIM + AMIKASIN ETKINLIGININ KARSILASTIRILMASI

Akan H., Koc H., Aydogdu I., İLHAN ., Beksac M., Gurman G., ...Daha Fazla

Mikrobiyoloji Bulteni, cilt.29, sa.2, ss.131-135, 1995 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 2
  • Basım Tarihi: 1995
  • Dergi Adı: Mikrobiyoloji Bulteni
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.131-135
  • Lokman Hekim Üniversitesi Adresli: Evet

Özet

Two antibiotic regimens were assessed, Sulbactam/Cefoperazone (2 g q 12 h) + Amikacin (0.5 g q 12h) (SP+A) and Ceftazidime (2 g q 8 h) + Amikacin (0.5 g q 12h) (C+A), for initial empiric therapy in febrile neutropenic patients with hematological problems. In an open randomized trial of 106 evaluable febrile episodes, 53 were treated with SP+A and 53 were treated with C+A. In 81% of the episodes neutropenia was severe (Absolute neutrophil count (ANC) < 500/μ3). There were 23.6% documented bacteremias whereas 10% were clinically defined infections without bacteremia. In positive blood cultures Gram negative microorganisms dominated (60% vs 40%). The treatment was successful at the end of 72 hours in 73% of the SP+A group and 57% of the C+A group (p>0.05). When 5 days without fever was taken into consideration the rates were 69% and 52% respectively (p>0.05). Toxicity was comparable. In conclusion both regimens were equally effective and well tolerated as initial therapy for neutropenic patients with fever.